What happens to regulatory T cells in multiple myeloma

被引:0
|
作者
Chen, Huixian [1 ,2 ]
Wang, Xueling [1 ,3 ]
Wang, Yan [4 ]
Chang, Xiaotian [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Med Res Ctr, Qingdao 266003, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao 266003, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Pediat, Jinan 250012, Peoples R China
关键词
TRANSCRIPTION FACTOR FOXP3; NATURAL-KILLER-CELL; PERIPHERAL-BLOOD; BONE-MARROW; SUPPRESSOR-CELLS; CD127; EXPRESSION; DENDRITIC CELLS; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN (IL)-2; ANTITUMOR IMMUNITY;
D O I
10.1038/s41420-023-01765-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells. In patients with MM, there are abnormalities in the number, function and distribution of Tregs, and these abnormalities may be related to the disease stage, risk grade and prognosis of patients. During the treatment, Tregs have different responses to various treatment regiments, thus affecting the therapeutic effect of MM. It is also possible to predict the therapeutic response by observing the changes of Tregs. In addition to the above, we reviewed the application of Tregs in the treatment of MM. In conclusion, there is still much room for research on the mechanism and application of Tregs in MM.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Chimeric Antigen Receptor T Cells in Multiple Myeloma
    Shah, Parth
    Sperling, Adam S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1089 - 1105
  • [42] Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma
    Brown, Ross
    Suen, Hayley
    Favaloro, James
    Yang, Shihong
    Ho, P. Joy
    Gibson, John
    Joshua, Douglas
    ONCOIMMUNOLOGY, 2012, 1 (09) : 1658 - 1660
  • [43] Highly preserved polyclonal regulatory T cells (Tregs) can dominate effector functions in multiple myeloma patients
    Foglietta, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 102 - 102
  • [44] CAR T-cells in patients with multiple myeloma
    Mateos, Maria-Victoria
    Gonzalez-Calle, Veronica
    FARMACIA HOSPITALARIA, 2021, 45 (05) : 219 - 220
  • [45] Clinical experience of CAR T cells for multiple myeloma
    Simmons, Gary L.
    Satta, Toshihisa
    Puglianini, Omar Castaneda
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (03)
  • [46] CAR T cells in multiple myeloma: lessons learned
    Prasad, Vinay
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (08) : 563 - 564
  • [47] Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
    Feng, Xiaoyan
    Zhang, Li
    Acharya, Chirag
    An, Gang
    Wen, Kenneth
    Qiu, Lugui
    Munshi, Nikhil C.
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4290 - 4300
  • [48] Regulatory T cells (Tregs) are highly preserved in multiple myeloma patients and can dominate effector functions.
    Foglietta, Myriam
    Mariani, Sara
    Castella, Barbara
    Coscia, Marta
    Godio, Laura
    Zappia, Serena
    Boccadoro, Mario
    Massaia, Massimo
    BLOOD, 2006, 108 (11) : 198A - 198A
  • [49] Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma
    Feng, Xiaoyan
    Acharya, Chirag
    An, Gang
    Wen, Kenneth
    Zhang, Li
    Kalbasi, Alireza
    Qiu, Lugui
    Munshi, Nikhil C.
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    BLOOD, 2016, 128 (22)
  • [50] Regulatory T cells CD8 regulatory T cells: What's old is now new
    Wang, Yuan Min
    Alexander, Stephen I.
    IMMUNOLOGY AND CELL BIOLOGY, 2009, 87 (03): : 192 - 193